GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

opevesostat   Click here for help

GtoPdb Ligand ID: 13856

Synonyms: Compound 185 [WO2018115591A1] [1] | MK-5684 | MK5684 | ODM-208 | ODM208
Compound class: Synthetic organic
Comment: Opevesostat (ODM-208; MK-5684) is a non-steroidal inhibitor of the cytochrome P450 11A1 (CYP11A1) [2] that catalyses the conversion of cholesterol to pregnenolone. This is the first rate-liming step in steroid hormone biosynthesis. Opevesostat was developed for antineoplastic activity against hormone-driven tumour cells, in which the inhibitor blocks steroid hormone biosynthesis and disrupts proliferation. An important caveat of this mechanistic apporach is that during treatment the steroids that are essential for life (glucocorticoids and mineralocorticoids) must be replaced at physiological doses.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 84.53
Molecular weight 418.51
XLogP 1.03
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CS(=O)(=O)N1CCC(CC1)COC2=COC(=CC2=O)CN3CC4=C(C=CC=C4)C3
Isomeric SMILES CS(=O)(=O)N1CCC(CC1)COC2=COC(=CC2=O)CN3CC4=CC=CC=C4C3
InChI InChI=1S/C21H26N2O5S/c1-29(25,26)23-8-6-16(7-9-23)14-28-21-15-27-19(10-20(21)24)13-22-11-17-4-2-3-5-18(17)12-22/h2-5,10,15-16H,6-9,11-14H2,1H3
InChI Key LHVKCOBGLZGRQZ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Belle DB, Makela M, Passiniemi M, Pietikainen P, Rummarkko P, Tiainen E, Vaismaa M, Wohlfahrt G. (2018)
Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors.
Patent number: WO2018115591A1. Assignee: Orion Corporation. Priority date: 21/12/2017. Publication date: 28/06/2018.
2. Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, Karlsson S, Rummakko P, Simola O, Wohlfahrt G et al.. (2022)
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Mol Cancer Ther, 21 (12): 1765-1776. [PMID:36129801]
3. (2024)
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
NEJM Evid, 3 (2): EVIDx2300368. [PMID:38349784]